Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Onconephrology
What is your approach to re-challenging patients with immune checkpoint inhibitors whom developed predominately acute tubular injury without acute interstitial nephritis?
Related Questions
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
Do you recommend holding ACE inhibitors, ARBs, and SGLT2 inhibitors for patients with chronic kidney disease and malignancy who are about to start high-dose intravenous methotrexate?
Would you continue to monitor urinary protein levels and dose adjust axitinib in a patient with metastatic malignancy who is now dialysis dependent but has residual renal function?
Thoughts about using Fecal transplant as a treatment option for recurrent difficult to treat C diff infection in an elderly kidney transplant patient.
What is the best way to assess exercise capacity in kidney transplantation candidates to predict post-transplant outcomes?
How would you treat idiopathic isolated renal TMA diagnosed on renal biopsy without evidence of MAHA?
How do you approach selecting a dialysis modality for a patient with advanced CKD who is interested in home therapy but has a history of medication non-adherence and poor attendance at clinic appointments?
Are there instances when you would prescribe a phosphate binder to an ESKD patient on hemodialysis who has a phosphorus level in the target range of less than 5.5 mg/dL?
Would you recommend the use of an ACE inhibitor to patients with Type 1 diabetes mellitus who are normotensive but have persistent moderate proteinuria?
How do you advise a patient with CKD who wants to take an herbal medication that is not known to be nephrotoxic, given that herbal medications are not regulated?
